Low-grade serous ovarian cancer is Distinct and Different

Low-grade serous ovarian cancer (LGSOC) is a rare ovarian cancer that is insidious, persistent, and ultimately fatal.1-5 It is molecularly and histopathologically distinct from high-grade serous ovarian cancer (HGSOC). Clinically, it requires different treatment.1,6,7

LEARN MORE ABOUT LGSOC

Signs and symptoms of LGSOC are nonspecific

Due to LGSOC symptoms being nonspecific, the disease may initially be misdiagnosed, significantly delaying an accurate diagnosis.8,9 In fact, ~90% of patients are diagnosed with LGSOC at an advanced stage.3,10

LOOK CLOSER AT DIAGNOSING LGSOC

LGSOC treatment options remain suboptimal

Current LGSOC treatments offer poor to moderate response with poor tolerability.5,11-21 With no specific FDA-approved treatment options, LGSOC can be an overwhelming diagnosis and the beginning of a very long patient journey.7,22

EXPLORE MANAGEMENT OF LGSOC

What’s ahead?

Emerging treatment options

Recent advances in the biological understanding of the mechanism of disease have opened up new targets and pathways for research to explore.23,24

DISCOVER INNOVATIVE APPROACHES

Resources for you
and your patients

Find downloadable materials, videos, educational materials, and helpful links in one easy-to-access location.

FIND RESOURCES AND SUPPORT
  1. Babaier A, Mal H, Alselwi W, et al. Low-grade serous carcinoma of the ovary: the current status. Diagnostics (Basel). 2022;12(2):458.
  2. Ciucci A, Zannoni GF, Buttarelli M, et al. Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment. Oncotarget. 2016;7(42):68033-68043.
  3. Gershenson DM, Bodurka DC, Lu KH, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol. 2015;33(24):2675-2682.
  4. Gershenson DM, Cobb LP, Westin SN, et al. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): determinants of relapse and disease-free survival. Gynecol Oncol. 2022;167(2):139-145.
  5. Monk BJ, Grisham RN, Banerjee S, et al. MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J Clin Oncol. 2020;38(32):3753-3762.
  6. Gershenson DM. Low-grade serous carcinoma of the ovary or peritoneum. Ann Oncol. 2016;27(Suppl 1):i45-i49.
  7. Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: state of the science. Gynecol Oncol. 2020;156(3):715-725.
  8. Harvard Health. Certain symptoms may be early signs of ovarian cancer. Accessed July 9, 2024. https://www.health.harvard.edu/cancer/certain-symptoms-may-be-early-signs-of-ovarian-cancer
  9. Gockley A, Melamed A, Bregar AJ, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol. 2017;129(3):439-447.
  10. De Decker K, Wenzel HHB, Bart J, et al. Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: a nationwide study. Acta Obstet Gynecol Scand. 2023;102(3):246-256.
  11. Gershenson DM, Miller A, Brady WE, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553.
  12. American Society of Clinical Oncology (ASCO) Post. GOG 3026: durable responses with ribociclib plus letrozole in low-grade serous ovarian cancer. Accessed July 9, 2024. https://ascopost.com/issues/may-25-2023/gog-3026-durable-responses-with-ribociclib-plus-letrozole-in-low-grade-serous-ovarian-cancer/
  13. Ricciardi E, Baert T, Ataseven B, et al. Low-grade serous ovarian carcinoma. Geburtsh Frauenheilk. 2018;78(10):972-976.
  14. Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134-140.
  15. Femara® [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals; 2014.
  16. Arimidex® [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP.; 2010.
  17. Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2):365-372.
  18. Avastin® [Prescribing Information]. San Francisco, CA: Genentech, Inc.; 2009.
  19. Lazurko C, Linder R, Pulman K, et al. Bevacizumab treatment for low-grade serous ovarian cancer: a systematic review. Curr Oncol. 2023;30(9):8159-8171.
  20. Grisham RN, Manning-Geist BL, Chui MH. The highs and lows of serous ovarian cancer. Cancer. 2023;129(17):2613-2620.
  21. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122-136.
  22. Banerjee SN, Ring KL, Nieuwenhuysen EV, et al. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J Clin Oncol. 2023;41(suppl 16):5515.
  23. Grisham RN, Manning-Geist BL, Chui MH. The highs and lows of serous ovarian cancer. Cancer. 2023;129(17):2613-2620.
  24. Kun E, Tsang YTM, Ng CW, et al. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev. 2021;92:102137.
Discover clinical trials

© 2024 Verastem, Inc. All Rights Reserved. NP-US-24-0179

The Verastem Oncology name and logo are trademarks of Verastem, Inc. All other trademarks mentioned on this website are property of their respective owners.

Redirection notice

You are now leaving this Verastem Oncology website and are going to an external website that is independently operated and not managed by Verastem Oncology. Verastem Oncology assumes no responsibility for the website. If you do not wish to leave this website, click Cancel. Or click OK to continue.

Cancel
OK

This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Privacy Policy.

Accept all

This information is for U.S. Healthcare Professionals.

Please confirm that you are a U.S. Healthcare Professional

Close
Confirm